3 results match your criteria: "Bom Jesus Hospital[Affiliation]"

Takayasu's arteritis is a granulomatous vasculitis of unknown etiology that affects mainly the aorta and its branches. As a result of intimal fibroproliferation, segmental stenosis, occlusion, dilatation, and aneurysmal formation of the involved vessels may develop. It is an uncommon disease and usually affects young Asian female patients during the second and third decades of life.

View Article and Find Full Text PDF

Infliximab for reactive arthritis secondary to Chlamydia trachomatis infection.

Rheumatol Int

March 2010

Department of Internal Medicine and Rheumatology, Bom Jesus Hospital, Ponta Grossa, PR, Brazil.

Reactive arthritis is an autoimmune disease that develops 2-4 weeks after a triggering infection, resulting mainly in synovitis/enthesitis of the lower limbs, but with a wide array of possible extra-articular manifestations. Most of the cases are self-limited, lasting some weeks to months, and respond well to nonsteroidal anti-inflammatory drugs (NSAIDs), but a considerable number of cases (about 20%) run a chronic disabling course, requiring immunosuppressants (methotrexate, sulphasalazine) to adequate control of the inflammatory symptoms. We describe, for the first time to our knowledge, a case of a Chlamydia trachomatis-related reactive arthritis refractory to methotrexate and sulphasalazine that was successfully treated with the monoclonal antibody anti-TNF-alpha and infliximab.

View Article and Find Full Text PDF

Idiopathic orbital inflammatory disease successfully treated with rituximab.

Clin Rheumatol

February 2009

Department of Internal Medicine and Rheumatology, Bom Jesus Hospital, Ponta Grossa, PR, Brazil.

We report a case of a 66-year-old Caucasian female with a diagnosis of idiopathic orbital inflammatory disease (OID) refractory to azathioprine therapy. The coexistence of diabetes mellitus represented a relative contraindication to chronic prednisone use. After two infusions of rituximab, a chimeric anti-CD20+ antibody, ophthalmic signs and symptoms remarkably improved.

View Article and Find Full Text PDF